Zoetis Inc - Class A (ZTS) Quality Analysis

Zoetis exhibits outstanding profitability metrics that meet or exceed the high thresholds in the GoodMoat framework. An operating margin of 37.8% and a profit margin of 28.2% are exceptionally strong, indicating significant pricing power and cost control. The return on equity of 80.2% is far above the 15-20% benchmark for high ROIC, suggesting the company generates enormous profits from its invested capital. This level of profitability is a hallmark of a quality business with a potential moat. However, the quality assessment reveals a mixed picture. The 3.0% YoY revenue growth is low and does not meet the framework's standard for 'consistent, double-digit' growth, raising a flag on that indicator. The debt/equity ratio of 2.77 is high, indicating a leveraged balance sheet, though this is common in the pharmaceutical industry for funding R&D and acquisitions. The 4.4% FCF yield is positive but modest. Compared to peers in specialty pharma, Zoetis's margins and returns are typically best-in-class, supported by its dominant position in the animal health market, strong brand portfolio, and deep customer relationships in veterinary clinics, which align with the moat criteria of Switching Costs and Brand & Culture. The key question for a value investor is whether these high returns are sustainable or at risk of mean reversion given the slowing top-line growth.